Ustekinumab biosimilar (CSPC Jushi)

Primary objective: To evaluate the consistency of efficacy between ustekinumab injection and Xidalun® in the treatment of moderate to severe plaque psoriasis. Secondary objective: To evaluate the efficacy of ustekinumab injection and Xidalun® in the treatment of moderate to severe plaque psoriasis based on secondary efficacy endpoints. To evaluate the safety and tolerability of ustekinumab injection and Xidalun® in the treatment of patients with moderate to severe plaque psoriasis. To evaluate the immunogenicity of ustekinumab injection and Xidalun® in patients with moderate to severe plaque psoriasis. To evaluate the PK characteristics of ustekinumab injection and Xidalun® in patients with moderate to severe plaque psoriasis.